Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages

Gut

Volumn 64, Issue 11, 2015, Pages 1783-1789

  Yu, Jun ^a   Blackford, Amanda L ^a   Dal Molin, Marco ^a   Wolfgang, Christopher L ^a   Goggins, Michael ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER REGISTRY; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENERAL ASPECTS OF DISEASE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SEX DIFFERENCE; TIME TO PROGRESSION; ADENOCARCINOMA; DISEASE COURSE; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; TIME FACTOR; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; TIME FACTORS;

EID: 84947570345     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308653     Document Type: Article

References (37)

1. Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012;142:796-804.
2. Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011;106:946-54.
3. Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010;16:5028-37.
4. Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009;58:1410-18.
5. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006;4:766-81.
6. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004;2:606-21.
7. Brentnall T, Bronner M, Byrd D, et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999;131:247-55.
8. Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009;104:2175-81.
9. Vasen HF, Wasser M, van Mil A, et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-leiden mutation. Gastroenterology 2011;140:850-6.
10. Brune K, Abe T, Canto M, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 2006;30:1067-76.
11. Canto MI, Harinck F, Hruban RH, et al. International consensus recommendations on the management of patients with increased risk for familial pancreatic cancer (The Cancer of the Pancreas Screening (CAPS) consortium summit). Gut 2013;62:339-47.
12. Tanaka M, Fernandez-Del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12:183-97.
13. Norris AL, Roberts NJ, Jones S, et al. Familial and sporadic pancreatic cancer share the same molecular pathogenesis. Fam Cancer 2014. In press.
14. Lennon AM, Wolfgang CL, Canto MI, et al. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res 2014;74:3381-9.
15. Kanda M, Sadakari Y, Borges M, et al. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol 2013;11:719-30.
16. Khashab MA, Yong E, Lennon AM, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc 2011;73:691-6.
17. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-17.
18. Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, et al. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 2012;152:S43-9.
19. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199-210; discussion 1210-1191.
20. de Jong MC, Li F, Cameron JL, et al. Re-evaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol 2011;103:656-62.
21. Honda O, Johkoh T, Sekiguchi J, et al. Doubling time of lung cancer determined using three-dimensional volumetric software: comparison of squamous cell carcinoma and adenocarcinoma. Lung Cancer 2009;66:211-17.
22. Nishida K, Kaneko T, Yoneda M, et al. Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis. J Surg Oncol 1999;71:140-6.
23. Gerlee P. The model muddle: in search of tumor growth laws. Cancer Res 2013;73:2407-11.
24. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-27.
25. Kanda M, Knight S, Topazian M, et al. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 2013;62:1024-33.
26. Klein AP, Lindstrom S, Mendelsohn JB, et al. An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS ONE 2013;8:e72311.
27. Klein AP. Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer 2013;13:66-74.
28. Chang KJ, Parasher G, Christie C, et al. Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups. Cancer 2005;103:349-57.
29. Wray CJ, Castro-Echeverry E, Silberfein EJ, et al. A multi-institutional study of pancreatic cancer in Harris County, Texas: race predicts treatment and survival. Ann Surg Oncol 2012;19:2776-81.
30. Arnold LD, Patel AV, Yan Y, et al. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Cancer Epidemiol Biomarkers Prev 2009;18:2397-405.
31. James TA, Sheldon DG, Rajput A, et al. Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer 2004;101:2722-6.
32. Anderson MA, Zolotarevsky E, Cooper KL, et al. Alcohol and tobacco lower the age of presentation in sporadic pancreatic cancer in a dose-dependent manner: a multicenter study. Am J Gastroenterol 2012;107:1730-9.
33. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-79.
34. Axelson H, Fredlund E, Ovenberger M, et al. Hypoxia-induced dedifferentiation of tumor cells - a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 2005;16:554-63.
35. Bull K, Spiegelhalter DJ. Survival analysis in observational studies. Stat Med 1997;16:1041-74.
36. Cain KC, Harlow SD, Little RJ, et al. Bias due to left truncation and left censoring in longitudinal studies of developmental and disease processes. Am J Epidemiol 2011;173:1078-84.
37. Park HS, Lloyd S, Decker RH, et al. Limitations and biases of the Surveillance, Epidemiology, and End Results database. Curr Probl Cancer 2012;36:216-24.